Research programme: caspase-3 inhibitors - Telik
Latest Information Update: 03 Apr 2007
At a glance
- Originator Telik
- Mechanism of Action Caspase-3 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Stroke
Most Recent Events
- 09 Oct 2001 Preclinical development for Stroke in USA (Unknown route)